1. Home
  2. GOOS vs OMER Comparison

GOOS vs OMER Comparison

Compare GOOS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canada Goose Holdings Inc. Subordinate Voting Shares

GOOS

Canada Goose Holdings Inc. Subordinate Voting Shares

HOLD

Current Price

$11.93

Market Cap

1.1B

Sector

N/A

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.93

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOOS
OMER
Founded
1957
1994
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
894.8M
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
GOOS
OMER
Price
$11.93
$11.93
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$12.60
$32.50
AVG Volume (30 Days)
1.0M
1.4M
Earning Date
02-05-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$1,067,658,612.00
N/A
Revenue This Year
$8.87
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
$75.41
N/A
Revenue Growth
10.42
N/A
52 Week Low
$6.73
$2.95
52 Week High
$15.43
$17.65

Technical Indicators

Market Signals
Indicator
GOOS
OMER
Relative Strength Index (RSI) 45.14 50.35
Support Level $11.67 $11.00
Resistance Level $12.42 $11.46
Average True Range (ATR) 0.62 0.60
MACD 0.00 -0.00
Stochastic Oscillator 53.58 60.45

Price Performance

Historical Comparison
GOOS
OMER

About GOOS Canada Goose Holdings Inc. Subordinate Voting Shares

Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: